The U.S.
IVD for Autoimmune Diseases Market was valued at USD 4.0 billion in
2015 and is expected to reach a value of USD 4.74 billion by 2024. The U.S. Laboratory Developed Test (LDT) for
autoimmune diseases was valued at USD 830.9 million in 2015. The high
prevalence of autoimmune disorders, growing awareness about these ailments,
growing demand for technologically developed & high performance products,
and high investments in research are the driving factors for the expanding
growth of the market.
These health problems are second leading cause
of chronic illness in the U.S. and are amongst the leading causes of deaths in
the U.S. women. They have an adverse impact on the work productivity and the
quality of life of patients and form an economic burden greatly affecting the
healthcare spending in the U.S. The National Institute of Health estimates the
direct healthcare costs associated with these disorders accounted for around
USD 100 billion, whereas the cancer costs accounted for USD 57 billion.
A large number of people suffering from these
disorders and rising prevalence at an alarming rate resulting in an increase of
healthcare spending in the U.S. are all priority concerns, and is thus are
expected to drive growth. Furthermore, the complications resulting from such
health hazards like damage to internal organs, loss of mobility, and risk of
death make it crucial for early diagnosis and intervention of such conditions.
The rising awareness about these conditions is expected to lead market growth.
It is believed by number of researchers that
the increase in the number of autoimmune diseases globally is due to the
genetic predisposition and environmental factors. But there is very little
knowledge about what exactly in the environment triggers the occurrence of
autoimmune diseases. and mainly focused on commercial kits that are widely used
by laboratories.
The FDA regulates IVD as medical devices however
in the past it did not use its authority to regulate LDT. The FDA later
announced that it would enforce its medical device regulatory authority to
regulate the LDTs. Some researchers believe that the FDA regulation on LDTs
would lead to an increase in the time and cost required to develop the tests.
Access Full Research Report@ http://www.grandviewresearch.com/industry-analysis/us-in-vitro-diagnostics-ivd-laboratory-developed-tests-ldt-autoimmune-diseases-market/request
Further Key Findings from the Study Suggest:
- In
2015, the IVD for rheumatoid arthritis was the leading segment with a
revenue share of 14.05% and the LDT for rheumatoid arthritis had a share
of 13.2%. The large number of diagnostic tests available for it as well as
the high prevalence of the disease contributed to the market share.
- In
2015, clinical chemistry was the leading segment with a market share of
35.6% in the IVD and 34.1% in the LDT. The diagnosis of autoantibodies in
the blood is the most commonly employed diagnosis, thus contributing to
the large share.
- Some
key participants in this field include Becton, Dickinson and Company;
Roche Diagnostics; Abbott Laboratories; Bio-Rad Laboratories, Inc.;
Danaher Corporation; SQI Diagnostics; Omega Diagnostics Group PLC;
ThermoFisher Scientific, Inc.; and some others. The key players focus
specially on developing innovative solutions for diagnosis. The
laboratories and institutes such as Mayo Medical Laboratories, Oklahoma
Medical Research Foundation, and Moleculera Labs also operate in the U.S.
in the same domain.
View
all related reports of this Category: http://www.grandviewresearch.com/industry/clinical-diagnostics
Grand
View Research has segmented
the U.S.
IVD and LDT For Autoimmune Diseases Market by application and
technology:
U.S. IVD and LDT for Autoimmune Diseases
Market: Application Outlook (Market Revenue in USD Billion, 2013 - 2024)
- Addison’s
Disease
- Ankylosing
Spondylitis
- Alopecia
Areata
- Rheumatoid
Arthritis
- Systemic
Lupus Erythematosus
- Systemic
Sclerosis
- Psoriasis
- Antiphospholipid
Antibody Syndrome
- Diabetes
Type 1
- Crohn’s
Disease
- Ulcerative
Colitis
- Narcolepsy
- Multiple
Sclerosis
- Uveitis
- Others
U.S. IVD and LDT for Autoimmune
Diseases Market: Technology Outlook (Market Revenue in USD Billion,
2013 - 2024)
- Immunoassays
- Clinical
Chemistry
- Hematology
- Coagulation
- Microbiology
- Molecular
Diagnostics
Browse Press Release of this Report @ http://www.grandviewresearch.com/press-release/us-in-vitro-diagnostics-ivd-laboratory-developed-tests-ldt-autoimmune-diseases-market-analysis
------
About Grand View Research
Grand View
Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Contact:
Sherry James
Corporate Sales
Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free:
1-888-202-9519
Email:
sales@grandviewresearch.com
No comments:
Post a Comment